Skip to main content
. 2014 Oct 23;16(10):861–867. doi: 10.1016/j.neo.2014.08.012

Table 2.

Correlation between Clinicopathologic Characteristics and CEP17 Status.

Variable n (%) CEP17 Status
P
Normal Duplicated
CEP17 137 124 (90.5) 13 (9.5)
Age, years ≤ 50 65 (47.5) 61 (49) 4 (30.8) .206
> 50 72 (52.5) 63 (51) 9 (69.2)
Menopausal status Premenopausal 63 (46) 59 (47) 4 (30.8) .247
Postmenopausal 74 (54) 65 (53) 9 (69.2)
Tumor stage II 49 (35.8) 44 (33.5) 5 (38.5) .830
III 88 (64.2) 80 (64.5) 8 (61.5)
Tumor status T2 38 (27.7) 33 (27) 5 (38.6) .606
T3 42 (30.7) 38 (30) 4 (30.7)
T4 57 (41.6) 53 (43) 4 (30.7)
Node status N0 46 (33.5) 42 (34) 4 (31) .538
N1 62 (45.5) 54 (44) 8 (61.5)
N2 25 (18) 24 (19) 1 (7.5)
N3 4 (3) 4 (3) 0 (0)
Tumor grade 1 11 (8) 11 (9) 0 (0) .499
2 62 (45) 55 (44) 7 (54)
3 64 (47) 58 (47) 6 (46)
ER Positive 86 (62.8) 77(62) 9 (69.2) .613
Negative 51 (37.2) 47 (38) 4 (30.8)
PR Positive 68 (49.6) 62 (50) 6 (46) .792
Negative 69 (50.4) 62 (50) 7 (54)
Ki67 status < 20% 73 (53.3) 66 (53) 7 (54) .937
≥ 20% 60 (50.4) 54 (43.5) 6 (46)
Missing data 4 (2.9) 4 (3) 0 (0)
HER2 Normal 112 (82) 103 (83) 9 (69) .166
Amplification 23 (17) 19 (15) 4 (31)
Missing data 2 (1) 2 (2) 0 (0)
TOP2A Normal 124 (91) 111 (89.5) 13 (100) .220
Amplification 7 (5) 7 (5.5) 0 (0)
Deletion 6 (4) 6 (5) 0 (0)
Neoadjuvant therapy FEC75/FAC60 84 (61.3) 76 (61) 8 (61.5) .986
EC-D 53 (38.7) 48 (39) 5 (38.5)
Surgical treatment Mastectomy 86 (62.9) 78 (62.9) 8 (61.5) .923
Lumpectomy 51 (37.1) 46 (37.1) 5 (38.5)
Pathologic response Complete 12 (8.7) 9 (7.3) 3 (23) .055
Residual disease 125 (91.3) 115 (92.7) 10 (77)

P values were calculated using the Chi-square test.